ALK and lung cancer: Tyrosine kinase inhibitors (TKI) such as gefitinib, osimertinib, and erlotinib target EGFR mutations found in lung cancers, lapatinib is a dual TKI that targets HER2/neu and EGFR mutations and is applied to advanced or metastatic breast cancer, vemurafenib and dabrafenib target BRAF mutations in melanoma, and crizotinib, ceritinib, and alectinib target anaplastic lymphoma kinase fusions in lung cancers (7, 81).